Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.632
AS - Asia 4.556
EU - Europa 3.504
SA - Sud America 767
AF - Africa 78
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.551
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.439
SG - Singapore 1.658
CN - Cina 963
HK - Hong Kong 787
RU - Federazione Russa 784
VN - Vietnam 749
BR - Brasile 626
IT - Italia 568
SE - Svezia 482
IE - Irlanda 481
DE - Germania 384
UA - Ucraina 210
GB - Regno Unito 153
CA - Canada 119
FI - Finlandia 102
AT - Austria 75
FR - Francia 73
KR - Corea 69
IN - India 67
ID - Indonesia 57
AR - Argentina 51
NL - Olanda 42
BD - Bangladesh 39
TR - Turchia 38
MX - Messico 35
PL - Polonia 35
ZA - Sudafrica 35
CO - Colombia 33
ES - Italia 23
JP - Giappone 22
EC - Ecuador 21
DK - Danimarca 20
IQ - Iraq 18
BE - Belgio 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
HN - Honduras 12
CZ - Repubblica Ceca 11
SA - Arabia Saudita 11
VE - Venezuela 11
BG - Bulgaria 9
MA - Marocco 9
BZ - Belize 8
PE - Perù 8
PK - Pakistan 8
AU - Australia 7
CH - Svizzera 7
KE - Kenya 7
UZ - Uzbekistan 6
CL - Cile 5
GR - Grecia 5
IL - Israele 5
IR - Iran 5
KZ - Kazakistan 5
LB - Libano 5
PT - Portogallo 5
PY - Paraguay 5
EU - Europa 4
PA - Panama 4
RS - Serbia 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
CI - Costa d'Avorio 3
LT - Lituania 3
NP - Nepal 3
OM - Oman 3
RO - Romania 3
AO - Angola 2
BB - Barbados 2
BO - Bolivia 2
BW - Botswana 2
DM - Dominica 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MY - Malesia 2
NI - Nicaragua 2
NO - Norvegia 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AP - ???statistics.table.value.countryCode.AP??? 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 16.544
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.254
Singapore 916
Hong Kong 781
Ashburn 666
Fairfield 484
Woodbridge 477
Dublin 454
Chandler 387
Houston 285
Wilmington 261
New York 248
Ho Chi Minh City 231
Frankfurt am Main 220
Beijing 199
Hanoi 193
Jacksonville 191
Santa Clara 186
Cambridge 183
Seattle 179
Dallas 178
Princeton 176
Los Angeles 149
Milan 146
Hefei 136
Dearborn 110
Lawrence 88
Buffalo 85
Moscow 81
Altamura 75
Seoul 67
São Paulo 67
Chicago 64
Vienna 64
Munich 56
San Diego 53
Shanghai 51
Nanjing 49
The Dalles 46
Jakarta 45
London 35
Guangzhou 32
Lachine 31
Boardman 30
Warsaw 30
Helsinki 29
Toronto 29
Nuremberg 28
Turku 28
Salt Lake City 27
Montreal 26
Haiphong 24
Rio de Janeiro 24
Rome 23
Andover 22
Da Nang 22
Council Bluffs 21
Brooklyn 20
Denver 19
Tokyo 19
Bogotá 18
Lissone 18
Stockholm 18
Thái Nguyên 18
Falls Church 17
Orem 17
Quận Bình Thạnh 17
Johannesburg 16
Mexico City 16
Tampa 16
Atlanta 15
Brasília 15
Changsha 15
Phoenix 15
Shenyang 15
Turin 15
Boston 14
Ha Long 14
Naples 14
Ottawa 14
Belo Horizonte 13
Hangzhou 13
Hebei 13
Ninh Bình 13
Norwalk 13
Brussels 12
Jinan 12
Lappeenranta 12
Amsterdam 11
Biên Hòa 11
Bắc Ninh 11
Can Tho 11
Huizen 11
Hải Dương 11
Nanchang 11
Redmond 11
Tegucigalpa 11
Vũng Tàu 11
Bologna 10
Buenos Aires 10
Chennai 10
Totale 10.658
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 447
Acute myeloid leukaemia niche regulates response to L-asparaginase 403
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 392
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis 336
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 334
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 315
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 296
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 295
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 276
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 262
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 259
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 252
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 250
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 249
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 247
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 244
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 240
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 235
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 225
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 222
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 222
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 221
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 212
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 211
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 208
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases 203
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 200
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 198
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 194
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 193
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 191
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 191
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 190
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 189
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 189
Outcome of very late relapse in children with acute lymphoblastic leukemia 185
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 183
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 181
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 176
Williams syndrome and mature B-Leukemia: A random association? 172
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 161
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 160
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 160
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 158
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 158
MTHFR 677C-->T mutation and neural-tube defects 157
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 155
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 154
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 153
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 152
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 152
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 148
First-Line Postremission Blinatumomab as Successful Toxicity-Sparing Strategy in a Boy with Cystic Fibrosis and Acute Lymphoblastic Leukemia 146
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 145
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 145
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 141
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target 139
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 136
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 136
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 133
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 124
Legionellosis in paediatrics [Legionellosi in pediatria] 123
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 121
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 119
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 118
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 116
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 115
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 113
Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers 110
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war 110
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 110
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial 108
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 107
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 107
NUP214–ABL1 fusion in childhood T-ALL 106
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 105
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach 103
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 101
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 98
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 95
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 92
Collaborative efforts driving progress in pediatric acute myeloid leukemia 92
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 90
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 89
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 88
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia 83
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 77
Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children with Acute Lymphoblastic Leukemia: Results of a Retrospective Survey 75
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 75
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia 74
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement 71
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data 71
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety 70
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 70
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 69
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 68
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium 68
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 66
The impact of the EU General Data Protection Regulation on childhood cancer research in Europe 63
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 63
Totale 16.400
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.119
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.119
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021994 0 0 0 0 0 243 136 150 98 163 97 107
2021/20221.311 85 99 105 164 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/20253.880 182 509 210 183 307 94 171 82 462 567 374 739
2025/20264.442 1.099 590 696 959 972 126 0 0 0 0 0 0
Totale 17.113